Cardiovascular risks of stopping antiplatelet therapy before non-cardiac surgery for patients with coronary stents.

The article provides an overview of the study conducted by Albaladejo and colleagues for identifying cardiovascular (CV) risks associated with the discontinuation of antiplatelet therapy before non-cardiac surgery in patients suffering from coronary stents. Interruption of antiplateley therapy, anaemia and severe renal insufficiency are shown to be some of the main factors associated with CV events. Recommendations for avoiding CV risks in these patients are also presented.